PMID- 36518323
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221221
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Proton therapy for isolated local regional recurrence of breast cancer after 
      mastectomy alone.
PG  - 925078
LID - 10.3389/fonc.2022.925078 [doi]
LID - 925078
AB  - PURPOSE/OBJECTIVES: To assess adverse events (AEs) and disease-specific outcomes 
      after proton therapy for isolated local-regional recurrence (LRR) of breast 
      cancer after mastectomy without prior radiotherapy (RT). MATERIALS/METHODS: 
      Patients were identified from a multi-institutional prospective registry and 
      included if diagnosed with invasive breast cancer, initially underwent mastectomy 
      without adjuvant RT, experienced an LRR, and subsequently underwent salvage 
      treatment, including proton therapy. Follow-up and cancer outcomes were measured 
      from the date of RT completion. RESULTS: Nineteen patients were included. 
      Seventeen patients were treated with proton therapy to the chest wall and 
      comprehensive regional lymphatics (17/19, 90%). Maximum grade AE was grade 2 in 
      13 (69%) patients and grade 3 in 4 (21%) patients. All patients with grade 3 AE 
      received > 60 GyE (p=0.04, Spearman correlation coefficient=0.5). At the last 
      follow-up, 90% of patients were alive with no LRR or distant recurrence. 
      CONCLUSIONS: For breast cancer patients with isolated LRR after initial 
      mastectomy without adjuvant RT, proton therapy is well-tolerated in the salvage 
      setting with excellent loco-regional control. All grade 3 AEs occurred in 
      patients receiving > 60 GyE.
CI  - Copyright (c) 2022 Laughlin, Bhangoo, Niska, Thorpe, Girardo, Anderson, Kosiorek, 
      McGee, Hartsell, Chang, Rossi, Tsai, Choi and Vargas.
FAU - Laughlin, Brady S
AU  - Laughlin BS
AD  - Department of Radiation Oncology Mayo Clinic, Phoenix, AZ, United States.
FAU - Bhangoo, Ronik S
AU  - Bhangoo RS
AD  - Department of Radiation Oncology Mayo Clinic, Phoenix, AZ, United States.
FAU - Niska, Joshua R
AU  - Niska JR
AD  - Department of Radiation Oncology Mayo Clinic, Phoenix, AZ, United States.
FAU - Thorpe, Cameron S
AU  - Thorpe CS
AD  - Department of Radiation Oncology Mayo Clinic, Phoenix, AZ, United States.
FAU - Girardo, Marlene E
AU  - Girardo ME
AD  - Health Sciences Research, Division of Biostatistics, Mayo Clinic, Scottsdale, AZ, 
      United States.
FAU - Anderson, Justin D
AU  - Anderson JD
AD  - Department of Radiation Oncology Mayo Clinic, Phoenix, AZ, United States.
FAU - Kosiorek, Heidi E
AU  - Kosiorek HE
AD  - Health Sciences Research, Division of Biostatistics, Mayo Clinic, Scottsdale, AZ, 
      United States.
FAU - McGee, Lisa A
AU  - McGee LA
AD  - Department of Radiation Oncology Mayo Clinic, Phoenix, AZ, United States.
FAU - Hartsell, William F
AU  - Hartsell WF
AD  - Northwestern Medicine Chicago Proton Center, Warrenville, IL, United States.
FAU - Chang, John H
AU  - Chang JH
AD  - ProCure Proton Therapy Center, Oklahoma City, OK, United States.
FAU - Rossi, Carl J
AU  - Rossi CJ
AD  - Scripps Proton Therapy Center, San Diego, CA, United States.
FAU - Tsai, Henry K
AU  - Tsai HK
AD  - ProCure Proton Therapy Center, Somerset, NJ, United States.
FAU - Choi, Isabelle J
AU  - Choi IJ
AD  - New York Proton Center, New York, NY, United States.
FAU - Vargas, Carlos E
AU  - Vargas CE
AD  - Department of Radiation Oncology Mayo Clinic, Phoenix, AZ, United States.
LA  - eng
PT  - Journal Article
DEP - 20221128
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9742552
OTO - NOTNLM
OT  - PMRT
OT  - breast cancer
OT  - local recurrence
OT  - post-mastectomy radiotherapy
OT  - protons
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/12/16 06:00
MHDA- 2022/12/16 06:01
PMCR- 2022/01/01
CRDT- 2022/12/15 02:20
PHST- 2022/04/21 00:00 [received]
PHST- 2022/11/10 00:00 [accepted]
PHST- 2022/12/15 02:20 [entrez]
PHST- 2022/12/16 06:00 [pubmed]
PHST- 2022/12/16 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.925078 [doi]
PST - epublish
SO  - Front Oncol. 2022 Nov 28;12:925078. doi: 10.3389/fonc.2022.925078. eCollection 
      2022.